National Institutes of Health · Forecast

Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)

What it funds

The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose early to definitive clinical trials. Trials testing drugs, devices, biologics, procedures, behavioral, social, economic, health services, or other biomedical or non-pharmacological interventions are of interest to this initiative. The trials should align with the research mission of the participating Institutes, Centers, and Offices (ICOs) of the NIH. The NOFO will utilize the R61/R33 activity code, a bi-phasic, milestone-driven award. The R61 phase provides support for planning activities, and the R33 phase provides support for a clinical trial, with a maximum project period of 7 years. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and relevant projects. Investigators with expertise in clinical trial planning, design, implementation, intervention development, and/or stakeholder engagement are encouraged to consider applying for the NOFO.

Who can apply

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

How to apply

Read the full notice and application package on the official listing, PAR-28-074 on Grants.gov. Questions go to [email protected]. Make sure your SAM.gov registration and Grants.gov or agency portal accounts are active well before the deadline, since registration can take several weeks.

Last updated by the agency Sep 29, 2026. Tracked by Federal Runway since Nov 17, 2026. Confirm details on the official notice.

Related opportunities